439 related articles for article (PubMed ID: 35968356)
1. Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.
Tufail M; Cui J; Wu C
Am J Cancer Res; 2022; 12(7):2920-2949. PubMed ID: 35968356
[TBL] [Abstract][Full Text] [Related]
2. The Breast Cancer Stem Cells Traits and Drug Resistance.
Zheng Q; Zhang M; Zhou F; Zhang L; Meng X
Front Pharmacol; 2020; 11():599965. PubMed ID: 33584277
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer under age 40: a different approach.
Ribnikar D; Ribeiro JM; Pinto D; Sousa B; Pinto AC; Gomes E; Moser EC; Cardoso MJ; Cardoso F
Curr Treat Options Oncol; 2015 Apr; 16(4):16. PubMed ID: 25796377
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques B; Mendes F; Martins D
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829916
[TBL] [Abstract][Full Text] [Related]
7. Evolving standards of care and new challenges in the management of HER2-positive breast cancer.
Choong GM; Cullen GD; O'Sullivan CC
CA Cancer J Clin; 2020 Sep; 70(5):355-374. PubMed ID: 32813307
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Response to Therapy: Can microRNAs Lead the Way?
Petrović N; Nakashidze I; Nedeljković M
J Mammary Gland Biol Neoplasia; 2021 Jun; 26(2):157-178. PubMed ID: 33479880
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Targeted Therapies in Breast Cancer.
Braga S
Methods Mol Biol; 2016; 1395():105-36. PubMed ID: 26910072
[TBL] [Abstract][Full Text] [Related]
10. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer.
Deng X; Apple S; Zhao H; Song J; Lee M; Luo W; Wu X; Chung D; Pietras RJ; Chang HR
Oncotarget; 2017 Jun; 8(24):38294-38308. PubMed ID: 28418843
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization and targeted therapeutic approaches in breast cancer.
Toss A; Cristofanilli M
Breast Cancer Res; 2015 Apr; 17(1):60. PubMed ID: 25902832
[TBL] [Abstract][Full Text] [Related]
12. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Vaccines: New Insights.
Benedetti R; Dell'Aversana C; Giorgio C; Astorri R; Altucci L
Front Endocrinol (Lausanne); 2017; 8():270. PubMed ID: 29081765
[TBL] [Abstract][Full Text] [Related]
14. Combining Multiscale Experimental and Computational Systems Pharmacological Approaches to Overcome Resistance to HER2-targeted Therapy in Breast Cancer.
Vaidya TR; Ande A; Ait-Oudhia S
J Pharmacol Exp Ther; 2019 Jun; 369(3):531-545. PubMed ID: 30898866
[TBL] [Abstract][Full Text] [Related]
15. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
[TBL] [Abstract][Full Text] [Related]
16. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer.
Tarantino P; Barroso-Sousa R; Garrido-Castro AC; McAllister SS; Guerriero JL; Mittendorf E; Curigliano G; Tolaney SM
Expert Rev Anticancer Ther; 2022 Feb; 22(2):141-153. PubMed ID: 34919490
[TBL] [Abstract][Full Text] [Related]
17. Resistance and Overcoming Resistance in Breast Cancer.
Luque-Bolivar A; Pérez-Mora E; Villegas VE; Rondón-Lagos M
Breast Cancer (Dove Med Press); 2020; 12():211-229. PubMed ID: 33204149
[TBL] [Abstract][Full Text] [Related]
18. Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity.
Houdaihed L; Evans JC; Allen C
Pharm Res; 2020 Jan; 37(3):39. PubMed ID: 31965330
[TBL] [Abstract][Full Text] [Related]
19. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
[TBL] [Abstract][Full Text] [Related]
20. Delineation of Pathogenomic Insights of Breast Cancer in Young Women.
Paul AM; George B; Saini S; Pillai MR; Toi M; Costa L; Kumar R
Cells; 2022 Jun; 11(12):. PubMed ID: 35741056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
